Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension safety study of fesoterodine in Japanese pediatric subjects with neurogenic detrusor overactivity
2020-004192-41Phase 3
- Sponsor
- Pfizer
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fesoterodine in detrusor hyperreflexia (DH) and neurogenic bladder, sponsored by Pfizer. Primary endpoint: Incidence of adverse events.
02
Drugs
fesoterodine
03
Conditions
detrusor hyperreflexia (DH)neurogenic bladder
Beyond the preview
Go deeper on 2020-004192-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004192-41.